ASH 2021 | Targetintg LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor responses in myeloma
In this video, Jooeun Bae, PhD, Dana-Farber Cancer Institute, Boston, MA, details the results of a study which targeted LAG-3, an immunosuppressive checkpoint molecule, and one of its ligands, GAL-3, to overcome immunosuppression and enhance anti-tumor responses in patients with multiple myeloma (MM). Dr Bae explains the methods of this study, including the various types of immune profiling conducted on patient samples, and compares the results of MM patients to patients with monoclonal gammopathy of undetermined significance (MGUS), patients with smoldering myeloma, and healthy individuals. Dr Bae further explains the expression rates of LAG-3 on CD4+ T-cells and CD8+ T-cells, and the effects of LAG-3 targeted antibody on T-cell proliferation and activity. To conclude, Dr Bae discusses the implications that these results may have in the development of cancer vaccines and emphasizes the benefits that LAG-3/GAL-3 blockade and other therapeutic combinations may have in the future of myeloma treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
